Literature DB >> 19799830

Psoriasis comorbidities.

Lyn Guenther1, Wayne Gulliver.   

Abstract

Psoriasis has been associated with a number of behavioral and systemic comorbidities, including psoriatic arthritis, anxiety, depression, obesity, hypertension, diabetes mellitus, hyperlipidemia, metabolic syndrome, smoking, cardiovascular disease, alcoholism, Crohn's disease, lymphoma, and multiple sclerosis. Many of these conditions have a similar immunologic pathogeneses. Canadian and international studies have not only confirmed the presence of these comorbidities but also have demonstrated that patients with psoriasis have a significantly reduced life span. Given that patients with psoriasis are often unaware of their comorbidities, they should be screened for these conditions and treated if required by their dermatologist and/or primary care physician. It is important to keep in mind that the comorbidities and drugs used to treat them have an impact on the choice of antipsoriatic treatment. In addition, comorbidities often preclude the use of traditional systemic agents. Recent studies have demonstrated that patients with preexisting comorbidities can be safely and effectively treated with biologic therapy. Furthermore, literature is evolving to suggest that better control of psoriasis might decrease cardiovascular mortality and prolong life.

Entities:  

Mesh:

Year:  2009        PMID: 19799830     DOI: 10.2310/7750.2009.00024

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  6 in total

1.  Which Psoriasis Patients Develop Psoriatic Arthritis?

Authors:  Kristine Busse; Wilson Liao
Journal:  Psoriasis Forum       Date:  2010

2.  A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Andrew Sohn; Mark Lebwohl
Journal:  J Clin Aesthet Dermatol       Date:  2011-02

3.  Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).

Authors:  A B Kimball; C Leonardi; M Stahle; W Gulliver; M Chevrier; S Fakharzadeh; K Goyal; S Calabro; W Langholff; A Menter
Journal:  Br J Dermatol       Date:  2014-07-16       Impact factor: 9.302

4.  Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

Authors:  B E Elewski; C S Baker; J J Crowley; Y Poulin; M M Okun; B Calimlim; Z Geng; O Reyes Servin; P A Rich
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-09-04       Impact factor: 6.166

5.  An integrative analysis to reveal that CLEC2B and ferroptosis may bridge the gap between psoriatic arthritis and cancer development.

Authors:  Xiaobin Li; Xiaohua Tao; Xiaoxia Ding
Journal:  Sci Rep       Date:  2022-08-27       Impact factor: 4.996

6.  Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis.

Authors:  Esra Adışen; Selda Uzun; Funda Erduran; Mehmet Ali Gürer
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.